Knowledge Accumulation and Industry Evolution
The Case of Pharma-Biotech

This book explores how the biotechnology and pharmaceutical sector is affected by innovation, growth and public policy.

Mariana Mazzucato (Edited by), Giovanni Dosi (Edited by)

9780521124003, Cambridge University Press

Paperback, published 17 December 2009

468 pages
22.9 x 15.2 x 2.6 cm, 0.68 kg

Review of the hardback: 'An enriching intellectual tour through the complex and dynamic landscape of the pharmaceutical industry. The rigorous analyses contained in the volume explore a variety of the most salient issues in the economics of innovation and industry evolution.' Gary Pisano, Harry E. Figgie, Jr., Harvard Business School

Written by internationally acclaimed experts in the economics of innovation, this volume examines how the biotechnology and pharmaceutical sector is affected by the dynamics of innovation, institutions, and public policy. It contributes both theoretically and empirically to the increasingly influential Schumpetarian framework in industrial economics, which places innovation at the centre of the analysis of competition. Both quantitative and qualitative studies are included, and this varied perspective adds to the richness of the volume's insights. The contributors explore different ideas regarding the historical evolution of technology in the sector, and how firms and industry structure have co-evolved with innovation dynamics. Important policy questions are considered regarding the future of innovation in this sector and its impact on the economy.

Figures
Tables
Contributors
1. Introduction: innovation, growth and industry evolution Giovanni Dosi and Mariana Mazzucato
Part I. Innovation and Industry Evolution: 2. Pharmaceutical innovation as a process of creative destruction Frank Lichtenberg
3. The evolution of pharmaceutical innovation Paul Nightingale and Surya Mahdi
4. Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals Myriam Mariani
5. Comments on Part I Lou Galambos
Part II. Firm Growth and Market Structure: 6. Growth and diversification patterns of the worldwide pharmaceutical industry Giulio Bottazzi, Fabio Paolli and Angelo Secchi
7. Heterogeneity in the firms' growth process: the case of the pharmaceutical industry Elena Cefis, Matteo Ciccarelli and Luigi Orsenigo
8. Entry, market structure and innovation in a history-friendly model of the evolution of the pharmaceutical industry Christian Garavaglia, Franco Malerba and Luigi Orsenigo
9. Comments on Part II Boyan Jovanovic
Part III. Policy Implications: 10. Effects of research tool patents and licensing on biomedical innovation John P. Walsh, Ashish Arora and Wesley Cohen
11. Upstream patents and public health: the case for generic testing of breast cancer Fabienne Orsi, Christine Sevilla and Benjamin Coriat
12. Competition, regulation and intellectual property management in GM foods: preliminary evidence from survey data Pierre Regibeau and Katherine Rockett
13. Governance, policy and industry strategies: agro-biotechnology and pharmaceuticals Joanna Chataway, Joyce Tait and David Wield
14. The dynamics of knowledge accumulation, regulation, and appropriability in the pharma-biotech sector: policy issues Luigi Orsenigo, Giovanni Dosi and Mariana Mazzucato.

Subject Areas: Business & management [KJ], Labour economics [KCF], Economics of industrial organisation [KCD]